Ascenion and Innovationsstarter Fonds Hamburg acquire equity in Hamburg start-up – innovative therapeutic approach enters clinical testing
Munich, 29 April 2020 – Scientists in Hamburg are aiming to improve therapy for HIV patients with a new gene- and cell-based method. At the Hamburg biotech start-up Provirex, they are developing a new therapeutic approach using ‘molecular scissors’ to cut HIV genes out of the genome of infected cells, thus eliminating the virus. This could at last make it possible to remove the virus rather than keeping it in check, as with current forms of treatment.
Ascenion GmbH and the Innovationsstarter Fonds Hamburg GmbH have acquired shares in the newly founded company. Provirex will press ahead with the further development of Brec1 recombinase technology, particularly with regard to simpler and more direct forms of drug delivery.
Read more
